Clinical observation of Feixin'an a self-made Chinese medicine formula in treating 30 cases of chronic obstructive pulmonary disease of  deficiency of qi and yin in stable stage

Zhen-yu DONG; Rui CAO; Wen-quan LI; Hong QUAN

doi:10.16025/j.1674-1307.2022.08.022

您当前的位置：

首页 >

文章列表页 >

Clinical observation of Feixin'an a self-made Chinese medicine formula in treating 30 cases of chronic obstructive pulmonary disease of deficiency of qi and yin in stable stage

更新时间：2023-02-15

- Clinical observation of Feixin'an a self-made Chinese medicine formula in treating 30 cases of chronic obstructive pulmonary disease of deficiency of qi and yin in stable stage
- Beijing Journal of Traditional Chinese Medicine Vol. 41, Issue 8, Pages: 907-911(2022)
- 作者机构：
  
  1.首都医科大学附属北京朝阳医院中医科，北京 100020
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2022.08.022
  CLC：
扫描看全文
董珍宇，曹锐，李文泉，等.肺心安联合西药治疗气阴两虚型慢性阻塞性肺疾病稳定期30例疗效观察［J］.北京中医药，2022，41（8）：907-911.

DONG Zhen-yu,CAO Rui,LI Wen-quan,et al.Clinical observation of Feixin'an a self-made Chinese medicine formula in treating 30 cases of chronic obstructive pulmonary disease of deficiency of qi and yin in stable stage[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(08):907-911.
董珍宇，曹锐，李文泉，等.肺心安联合西药治疗气阴两虚型慢性阻塞性肺疾病稳定期30例疗效观察［J］.北京中医药，2022，41（8）：907-911. DOI： 10.16025/j.1674-1307.2022.08.022.

DONG Zhen-yu,CAO Rui,LI Wen-quan,et al.Clinical observation of Feixin'an a self-made Chinese medicine formula in treating 30 cases of chronic obstructive pulmonary disease of deficiency of qi and yin in stable stage[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(08):907-911. DOI： 10.16025/j.1674-1307.2022.08.022.

摘要

目的,2,观察肺心安治疗气阴两虚型慢性阻塞性肺疾病（COPD）稳定期的临床疗效。,方法,2,选择2019年1月—2020年12月首都医科大学附属北京朝阳医院中医科门诊及病房收治的气阴两虚型COPD稳定期患者60例，肺功能Ⅱ~Ⅲ级，随机分为对照组与试验组，每组30例。对照组予西医基础治疗，试验组在西药基础上加肺心安，1袋/次，2次/d，12周为1个疗程，随访6个月。比较2组疗效，治疗前后中医证候积分、COPD评估测试（CAT）评分、改良英国医学研究学会呼吸困难指数量表（mMRC）评分、急性加重次数、实验室指标及不良反应。,结果,2,试验组总有效率96.67%，高于对照组83.33%，差异有统计学意义（,P,<,0.05）。治疗后，2组中医证候总积分、CAT评分、mMRC评分、血清缺氧诱导因子（HIF-1α）水平均较治疗前降低（,P,<,0.05），血清1，25-二羟维生素D,3,［1，25（OH）,2,D,3,］水平均较治疗前升高（,P,<,0.05），且试验组以上指标优于对照组，差异有统计学意义（,P,<,0.05）。所有患者治疗后均未见明显不良反应。,结论,2,肺心安联合西医基础治疗气阴两虚型COPD稳定期患者能够提高临床疗效，改善临床症状，减少急性加重次数。

Abstract

Objective,2,To observe the effect of Feixin'an in treating chronic obstructive pulmonary disease （COPD） of deficiency of Qi and Yin in the stable stage.,Methods,2,A total of 60 COPD patients in stable stage of deficiency of Qi and Yin with Grade II to Ⅲ lung function treated in Department of TCM of Beijing Chaoyang Hospital Affiliated to the Capital Medical University from January 2019 to December 2020 were randomly divided into a control group and an observation group with 30 cases in each group. The control group was treated with routine western medicine. On the basis of the routine western medicine，the observation group was also given Feixin'an with one bag each time， twice a day，12 weeks as a course， and follow-up for 6 months. The TCM clinical syndromes score， CAT score，mMRC score， acute aggravation times， laboratory indexes and adverse reactions in 2 groups were observed and compared before and after the treatment.,Results,2,The effective rate of the observation group was 96.67%， which was higher than that of the control group（,P,<,0.05）which was 83.33%， and the difference was statistically significant （,P,<,0.05）. After the treatment， TCM clinical syndromes score， CAT score， mMRC score and HIF-1α were more obviously alleviated than that before the treatment（,P,<,0.05）， serum 1，25-dihydroxyvitamin D,3,［1，25（OH）,2,D,3,］ were increased than that before the treatment in both two groups， the index of the experimental group was better than that of the control group and the difference was statistically significant （,P,<,0.05） No adverse reactions were found in both groups.,Conclusion,2,Feixin'an combined with routine treatment can enhance the clinical effect of chronic obstructive pulmonary disease （COPD） of deficiency of Qi and Yin in the stable stage， improve TCM symptoms，reduce the acute aggravation and improve the quality of life.

关键词

肺心安慢性阻塞性肺疾病稳定期气阴两虚型

Keywords

Feixin'anchronic obstructive pulmonary diseasestable stageQi and Yin deficiency

references

HURST JR,SIDDIQUI MK,SINGH B,et al. A systematic literature review of the humanistic burden of COPD[J].Int J Chron Obstruct Pulmon Dis. 2021,16:1303-1314.

WANG C,XU J,YANG L,et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH]study):a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.

李正欢,张晓云,陈杨,等.2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读（一）:稳定期药物管理[J].中国全科医学,2021,24(8):923-929.

中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志,2014,6(2):67-80.

李建生,李素云,余学庆.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志,2012,53(1):80-84.

王蕾,杨汀,王辰.2017年版慢性阻塞性肺疾病诊断、处理和预防全球策略解读[J].中国临床医生杂志,2017,45(1):104-108.

郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:61-65．

陈秀利,孙培莉,尤玲燕,等.CAT量表与稳定期COPD患者健康状态的关系[J].南京医科大学学报（自然科学版）,2013,33(4):511-514.

田建霞,陈晓香,王继苹.改良英国医学研究委员会呼吸困难量表评分、慢性阻塞性肺疾病评估测试评分与慢性阻塞性肺疾病患者肺功能的相关性及其对肺动脉高压的预测价值[J].实用心脑肺血管病杂志,2018,26(12):44-48.

陈麒,张学超,蔡淦,等.健脾化痰方治疗肺脾两虚型慢性阻塞性肺疾病临床疗效及对气道炎症影响评价[J].北京中医药,2017,36(4):294-298

唐诗环,王玥琦,廖强,等.固本止咳中药对慢性阻塞性肺疾病模型小鼠肺功能及SIgA的影响[J].北京中医药,2019,38(9):893-897,945.

王羽嘉,刘亚倩,吴巧敏,等.老年性慢性阻塞性肺疾病基于氧化应激机制的中西医病机及治疗[J].北京中医药,2020,39(4):354-357.

丁炎,崔湧,李悦,等.维生素D及其受体在吸烟患者中表达水平的研究[J].山西医药杂志,2017,46(6):615-617.

祁永梅,马祥生,胡雪甫,等.TAT、25-(OH)D及D-D水平与COPD患者肺功能的相关性研究[J].河北医药,2019,41(9):1329-1332.

尹学信.慢性阻塞性肺疾病患者血清1,25-二羟维生素D3与病情程度的关系研究[J].中国现代药物应用,2021,15(8):29-32.

商娜,刘慧珍,李培兰,等.血清25-羟基维生素D缺乏与AECOPD临床分级的相关性研究[J].临床肺科杂志,2021,26(3):325-329.

张盛斌,郑吼真,张淇钏,等.血清25-羟维生素D水平与COPD急性加重期患者免疫炎症指标、CAT评分的相关性研究[J].广东药科大学学报,2020,36(5):719-723.

杨国建,李敏.1，25二羟维生素D3对哮喘小鼠的Ｒac1-IL33-ILC2通路的作用[J].实用医院临床杂志,2021,18(1):1-3.

张鹤,张沄,王宋平.1,25-二羟维生素D3通过TGF-β1/（Smad2/3）影响的ROS调节气道重塑[J].天津医药,2020,48(4):267-271.

MOKAS S,LARIVIERE R,LAMALICE L,et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification [J].Kidney Int,2016,90(3):598-609.

WANG LC,TANG YL,CHEN Y.HIF1A rs10873142 polymorphism is associated with risk of chronic obstructive pulmonary disease in a Chinese Han population: a case-control study[J].Bioscience Rep,2018,38(2):1-6.

陈丽君,陈娟霞,马丽婷,等.HIF-1α表达在 COPD 及健康人群的差异性分析[J].宁夏医学杂志,2021,43(3):229-231.

赵涛,李嘉颖.缺氧诱导因子1α在慢阻肺中的表达及肺血管重构的关系[J].临床肺科杂志,2016,21(1):57-60.

李文泉,孔文莹,张健,等.扶正固本治疗肺心病急性发作期气阴两虚型免疫功能改善的临床研究[J].中医杂志,1994,35(5):299-300.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰